Agreement termination notice period.

No definition available.

Name:	mack_AgreementTerminationNoticePeriod
Namespace Prefix:	mack_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of purchase commitment entered into as part of a collaboration.

+ References

No definition available.

+ Details

Name:	mack_CollaborationPurchaseCommitment
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents costs under collaboration agreement for which the Company is responsible paying.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementCostsCompanyResponsibility
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the expected development period from the effective date of agreement.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementExpectedDevelopmentPeriod
Namespace Prefix:	mack_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum cumulative obligation for milestone payments under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementMaximumMilestonePaymentObligation
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents an obligation related to a collaboration milestone that has been accrued, but not yet paid.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementMilestoneAccruedObligation
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of milestone payment made during the period under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementMilestonePayment
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the cumulative amount of milestone payment received during the period under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementMilestonePaymentsReceived
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the cumulative amount of nonrefundable, noncreditable upfront license fee received during the period under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementUpfrontLicenseFeeReceived
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_CollaborativeArrangementUpfrontPaymentObligation
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents deferred billed and billable milestones and development expenses.

+ References

No definition available.

+ Details

Name:	mack_DeferredBilledAndBillableMilestonesAndDevelopmentExpenses
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty amounts that the Company is entitled to as a result of sales of collaborators.

+ References

No definition available.

+ Details

Name:	mack_EntitledRoyaltyAmounts
Namespace Prefix:	mack_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue recognized during the period related to spending in excess of collaboration agreement budget for services performed

+ References

No definition available.

+ Details

Name:	mack_IncreasedRevenueRecognized
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the initial term of the License Agreement.

+ References

No definition available.

+ Details

Name:	mack_LicenseAgreementExpirationTermFromFirstSaleOfProduct
Namespace Prefix:	mack_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the term of the incremental renewal periods which automatically occur subsequent to the expiration of the previously-expired term of the License Agreement, unless notice of non-renewal is given by either party.

+ References

No definition available.

+ Details

Name:	mack_LicenseAgreementRenewalPeriodOne
Namespace Prefix:	mack_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum cumulative amount of milestone payments that can be received over the life of the license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	mack_MaximumCollaborativeArrangementMilestonePayments
Namespace Prefix:	mack_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the latest date upon which a milestone will be achieved.

+ References

No definition available.

+ Details

Name:	mack_MilestoneAchievementDate
Namespace Prefix:	mack_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the date a license and collaboration agreement is scheduled to terminate.

+ References

No definition available.

+ Details

Name:	mack_TerminationAgreementDate
Namespace Prefix:	mack_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name:	us-gaap_Assets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

+ Details

Name:	us-gaap_Liabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_ActavisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_BaxterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_PharmaEngineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=mack_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Nov. 10, 2009	Jul. 31, 2014	May 05, 2011	Mar. 31, 2012	Nov. 25, 2014	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenues	$ 14,842,000us-gaap_Revenues	$ 13,034,000us-gaap_Revenues
Deferred revenue, current	59,506,000us-gaap_DeferredRevenueCurrent								59,275,000us-gaap_DeferredRevenueCurrent
Agreement termination scheduled date	Dec. 17, 2014
Assets maintained related to Sanofi Agreement	127,020,000us-gaap_Assets								158,656,000us-gaap_Assets
Liabilities maintained related to Sanofi Agreement	255,842,000us-gaap_Liabilities								260,727,000us-gaap_Liabilities
Research and development expenses	35,679,000us-gaap_ResearchAndDevelopmentExpense	30,324,000us-gaap_ResearchAndDevelopmentExpense
Baxter [Member] \| Proportional Performance Model [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenues	14,800,000
Baxter [Member] \| Substantive or Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenues	0
Baxter [Member] \| License and Collaboration Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront license fee received			100,000,000
Royalty for improved products	The Company is also entitled to tiered, escalating royalties ranging from sub-teen double-digits to low twenties percentages of net sales of MM-398 in the Licensed Territory.
Notice period of termination	180 days
Deferred revenue	78,914,000								91,156,000
Deferred revenue, current	59,500,000
Baxter [Member] \| License and Collaboration Agreements [Member] \| Sales Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum amount of milestone payments that can be received	250,000,000
Baxter [Member] \| License and Collaboration Agreements [Member] \| Research and Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum amount of milestone payments that can be received	100,000,000
Baxter [Member] \| License and Collaboration Agreements [Member] \| Regulatory Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum amount of milestone payments that can be received	520,000,000
Baxter [Member] \| License and Collaboration Agreements [Member] \| Clinical Trials in Pancreatic Cancer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration agreement costs	98,800,000
Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront license fee received				60,000,000
Collaboration revenues	0
Milestone license fee received	25,000,000
Expected development period from the effective date of agreement				12 years
Assets maintained related to Sanofi Agreement	0
Liabilities maintained related to Sanofi Agreement	0
Sanofi [Member] \| License and Collaboration Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenues		13,034,000
Recognized revenue related to excess spending		5,800,000
Estimated total cost of this drug supply					4,300,000
PharmaEngine [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront license fees paid						10,000,000
PharmaEngine [Member] \| Development and Regulatory Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment obligation						80,000,000
PharmaEngine [Member] \| Sales Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment obligation						130,000,000
PharmaEngine [Member] \| Phase 3 Clinical Trial in Pancreatic Cancer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment							5,000,000
PharmaEngine [Member] \| License and Collaboration Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment			7,000,000
Milestone payment due date	Apr. 30, 2015
Research and development expenses	200,000	100,000
PharmaEngine [Member] \| License and Collaboration Agreements [Member] \| New Drug Application [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration milestone obligation, accrued	5,000,000
Actavis [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum amount of milestone payments that can be received								15,100,000
Notice period of termination	90 days
Milestone license fee received	3,800,000
Agreement expiration term respect to each product	10 years
Additional renewal term	2 years
Milestones and development expenses	$ 3,800,000								$ 3,800,000